What their data shows and what it still doesn't explain.

What happens when a blockbuster drug meets a common vitamin?

In this deep dive, we unpack Eli Lilly’s warning about tirzepatide mixed with vitamin B12, and the science behind the controversy.

A newly released preprint shows that when the two are combined, they can form a previously unknown molecular complex, detected in real world samples. Some products were also found to be significantly under strength, raising broader concerns about quality in the secondary market.

But while the chemistry is real, the key question remains unanswered:

does any of this actually matter for patients?

We break down:

what Lilly’s data actually proves

how the molecules interact at a structural level

why lab findings don’t automatically translate to real-world risk

and how this fits into the wider $100B GLP-1 market battle

This isn’t just a story about one drug or one impurity, it’s about the gap between analytical evidence and clinical reality, and what happens when patients are caught in the middle.